Physician profile
Luis Vinuela
NPI 1710943311
$7,289.55
in general payments reported to CMS, 2019-2025
23 companies · $1,067 in 2025
The $1,067 reported for 2025 was more than what 84% of Geriatric Psychiatry providers received nationally (typical 2025 total: $125).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $658 · 2020: $553 · 2021: $980 · 2022: $1,315 · 2023: $1,503 · 2024: $1,213 · 2025: $1,067.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,783.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,782.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,148.52 | 2021-2025 | Vraylar |
| Alkermes, INC. | $1,013.23 | 2019-2025 | Aristada, Lybalvi, Aristada Initio |
| Janssen Pharmaceuticals, INC | $926.18 | 2019-2025 | Invega Sustenna, Invega Trinza, Spravato |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $739.69 | 2020-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $521.02 | 2019-2025 | Abilify Asimtufii, Rexulti, Abilify Maintena |
| Takeda Pharmaceuticals U.S.A., INC. | $500.27 | 2019-2025 | Trintellix |
| Teva Pharmaceuticals USA, INC. | $453.57 | 2019-2025 | Austedo Xr, Uzedy, Austedo |
| Lundbeck LLC | $351.00 | 2019-2025 | Rexulti |
| Neurocrine Biosciences, INC. | $294.96 | 2019-2025 | Ingrezza |
| Vanda Pharmaceuticals INC. | $268.99 | 2019-2025 | Fanapt, Hetlioz |
| Axsome Therapeutics, INC. | $239.48 | 2022-2025 | Auvelity |
| Almatica Pharma LLC | $181.69 | 2021-2024 | Gralise, Loreev Xr |
| E.R. Squibb & Sons, L.L.C. | $137.86 | 2024-2025 | Cobenfy |
| Sunovion Pharmaceuticals INC. | $108.82 | 2020-2022 | |
| Corium, LLC | $105.98 | 2022-2023 | Azstarys, Adlarity |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Indivior INC. | $62.94 | 2021-2023 | Perseris |
| Allergan, INC. | $60.30 | 2019-2021 | |
| Neuronetics, INC. | $43.52 | 2019 | |
| Idorsia Pharmaceuticals US INC | $35.66 | 2023 | Quviviq |
| Merck Sharp & Dohme LLC | $34.55 | 2021-2022 | |
| Eisai INC. | $29.19 | 2020-2021 | |
| Shire North American Group INC | $17.85 | 2019 | |
| Noven Therapeutics, LLC | $14.28 | 2025 | Xelstrym |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Luis Vinuela listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.